Department of Pharmacy

Permanent URI for this collectionhttp://localhost:4000/handle/123456789/1931

Browse

Filters

20232

Settings

Author: search.filters.author.Jain, AnkitSubject: search.filters.subject.Nanoparticles

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Plant polysaccharides-based nanoparticles for drug delivery
    (Elsevier, 2023) Jain, Ankit
    Recently natural polysaccharides have gained attention for the design of nanoparticles (NPs) for the effective delivery of drugs. These polysaccharides have several advantages such as biodegradability, biocompatibility, and low cytotoxicity. Several studies have reported nanoparticle-based drug delivery systems showing effective localization of drugs into the target site. It provides a combined effect toward the development of biodegradable/biocompatible NPs with high potential of passive/active targeting and reduced undesirable side effects of the drug. Additionally, the size of NPs plays a key role in the use of these structures as drug/gene carriers as well as trans-membrane transporters. The plant polysaccharides also provide a large number of reactive groups, and specific targeting can be achieved by surface modification of NPs with targeting ligands. Moreover, the mucoadhesive properties of these polysaccharides could be used to prolong the retention time of drug delivery at the site of absorption. This chapter deals with the classification of polysaccharides, their advantages and disadvantages. It includes polysaccharides such as pectin, guar gum, alginate, gum tragacanth, gum acacia, locust bean gum, cellulose, starch, gum karaya, and cashew gum. This chapter also discusses the application of polysaccharides-based NPs in the treatment of cancer.
  • No Thumbnail Available
    Item
    Nano-formulated siRNA-based therapeutic approaches for cancer therapy
    (Elsevier, 2023-03) Jain, Ankit
    RNAi is a remarkable treatment strategy to knock down gene overexpression in a variety of disorders, including cancers. RNAi processes allow siRNAs to detect and degrade a homologous mRNA sequence in the cell. However, the limited potential of siRNA delivery to target cells, poor cellular uptake, off-target effect, and their breakdown by serum nucleases in systemic circulation are limiting factors for their therapeutic applications. Over the past few years, siRNA drugs are undergoing a period of clinical translation. Therefore, this review mainly highlights the state-of-the-art of nanocarriers for delivering siRNA cargos and their coadministration with anticancer drugs, along with their applications in cancer treatment. Besides, molecular manifestations, challenges in the delivery of siRNA, design, and development of siRNA-based delivery systems, merits, and demerits of different nanocarriers have been discussed. The endosomal trapping of siRNA is a major difficulty for most delivery strategies, influencing the therapeutic effect. To address this issue various approaches for siRNA release including pH-responsive release, membrane fusion, proton sponge effect, and photochemical disruption have been discussed. Finally, the current status of siRNA therapeutics in clinical trials is explored, providing a systematic and comprehensive overview of siRNA-based therapeutics for effective cancer treatment.